Campaign successes
Thanks to our amazing supporters like you, our campaigns are making things better for people living with or affected by breast cancer.
Together, we can make change happen
Our campaigns show that we do have the power to make change. Check out some of our campaign successes.
Our recent successes
-
Securing Trodelvy
For too long, women living with triple negative secondary breast cancer faced a lack of effective treatment options on the NHS. But Trodelvy, an exciting new drug, offered them the potential of more time to live.
Thanks to you, Trodelvy was approved for routine use on the NHS.
Campaigns, like this one, show we do have the power to make change.
-
Securing Olaparib
Olaparib is a potentially life-saving primary breast cancer drug that could reduce the risk of cancer returning or progressing to incurable secondary breast cancer.
Thanks to you, olaparib was approved for routine use on the NHS in England in 2023. And it’s now available in Wales, Scotland and Northern Ireland too.
-
Keeping Kadcyla
Women with incurable secondary breast cancer have no time to lose. They need access to the drugs that can help them live well, for longer.
But in 2017, one of the most effective secondary breast cancer drugs was under threat of being removed from the NHS.
Our petition called on pharmaceutical company Roche and the National Institute for Health and Care Excellence (NICE) to do everything in their power to keep Kadcyla available.
115,898 of you signed our petition. And thanks to you, the lifeline drug was approved for routine use on the NHS.
-
Unlocking Kadcyla in Scotland
Thank you for signing our petition, to help transform treatment options for women with HER2 positive breast cancer in Scotland.
Thanks to your support, in April 2017 the Scottish Medicine Consortium announced a landmark decision to make the revolutionary cancer drug available on Scotland’s NHS.
-
Perjeta now
Women with incurable breast cancer simply want more time to live. Perjeta is a life-changing drug with extraordinary benefits, giving on average nearly 16 extra months of life.
In 2019, the Scottish Medicines Consortium (SMC) announced its decision to approve Perjeta for routine use in Scotland. This treatment is only available thanks to supporters like you.
